Primary cardiovascular disease prevention
Low-dose aspirin use in individuals without established cardiovascular disease. Recent guidelines limit routine use due to bleeding risk.
4 drugs
Also known as: Primary CV prevention aspirin
Marketing claims without evidence base
The drug is promoted for these uses outside international guidelines. Each entry below is analyzed against AEMPS, FDA, EMA, Cochrane and major RCTs.
- DAcetylsalicylic acidNot recommended · Antiplatelet agents (low dose) / NSAIDs (analgesic dose)Routine aspirin for primary prevention is not recommended. ASPREE, ARRIVE, and ASCEND trials showed that in moderate-risk patients, the reduction in ischemic events is offset by increased bleeding. USPSTF 2022 recommends against initiating aspirin in adults 60 and older for primary prevention. In adults 40–59 with a 10-year ASCVD risk of 10 % or more, the decision is individualized.
- FClopidogrelNot recommended · Antiplatelet agents – P2Y12 receptor inhibitorsClopidogrel is taken by healthy adults for blood thinning instead of or alongside aspirin in anti-aging protocols. ESC 2024 and ACC/AHA 2023 confine clopidogrel to secondary prevention in coronary artery disease, peripheral arterial disease, post-stenting and acute coronary syndrome. Healthy-adult hard-endpoint data are absent. Use creates increased bleeding risk without equivalent thromboembolic reduction.
- FTicagrelorNot recommended · Reversible P2Y12 receptor inhibitorTicagrelor is an antiplatelet drug, a reversible P2Y12 receptor inhibitor. It is prescribed for acute coronary syndrome and for secondary prevention after myocardial infarction (ESC 2024, ACC/AHA 2017). In biohacker and longevity circles, ticagrelor is occasionally promoted for primary CV prevention as a more modern alternative to aspirin. In people without confirmed coronary disease, stroke, or other high CV risk, no clinical studies of primary prevention with ticagrelor exist, and such prescription is dangerous. The drug has serious risks: severe bleeding (including life-threatening intracranial), dyspnea (common, in 14% of patients), bradycardia with syncope risk, and hyperuricemia. If ticagrelor was prescribed without confirmed ACS or post-MI, consider seeking a second opinion.
- FWarfarinNot recommended · Vitamin K antagonist anticoagulantsWarfarin is an indirect anticoagulant, a vitamin K antagonist. It is prescribed for atrial fibrillation with stroke risk, venous thromboembolism (DVT/PE), and prosthetic heart valves (ESC 2024, ACC/AHA 2023). In anti-aging circles, warfarin is taken for blood thinning outside these indications. In healthy adults, no clinical studies of prophylactic warfarin for primary CV prevention exist, and such prescription is dangerous. The drug has serious risks: narrow therapeutic window (requires regular INR monitoring), multiple food and drug interactions (especially vitamin K and CYP2C9 substrates), elevated hemorrhagic stroke risk in older adults, and bleeding at any site. If warfarin was prescribed for blood thinning outside atrial fibrillation, thrombosis, or a prosthetic valve, consider seeking a second opinion.
How to read tiers A–F
Evidence tiers belong to the drug-indication pair, not to the drug as a whole: the same substance can be A for one condition and F for another.
- AStrong evidence – first or second line in international guidelines
- BRecommended in selected cases
- CStudy data contradict each other
- DBenefit not proven, no documented harm
- FDocumented harm, or risk without benefit